Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Studying the Modification of Attention Bias Remotely After Trauma

NCT: NCT04888169 · COMPLETED

NCT IDNCT04888169
StatusCOMPLETED
Start Date2023-04-20
Completion2025-06-30
SponsorUniversity of California, San Francisco (OTHER)
First posted
Last updated

Brief Summary

The investigators will complete an entirely remote randomized controlled trial (RCT) comparing 14 sessions of attention bias modification (ABM), attention control training (ACT), placebo neutral attention training, and a final control condition with daily questions in 1,897 individuals with clinically significant Post-traumatic Stress Symptoms (PTSS) (defined as PCL-5 score ≥ 33). To assess effects of the training and control conditions, the investigators will administer tests of threat-related attention bias and variability, and self-report assessments of PTSS, depression, anxiety, and perceived stress at baseline, after one and two weeks of training, and at eight-week follow up. The investigators plan to screen and confirm interest from over 3,000 eligible participants over a period of 24 months to enroll and randomize 1,897 participants with the end goal of 1,232 completers (176 per condition).

Frequently Asked Questions

What is Studying the Modification of Attention Bias Remotely After Trauma?

Studying the Modification of Attention Bias Remotely After Trauma is a clinical trial registered under NCT04888169. Current status: COMPLETED.

What is the status of NCT04888169?

The current status of NCT04888169 (Studying the Modification of Attention Bias Remotely After Trauma) is: COMPLETED.

When did Studying the Modification of Attention Bias Remotely After Trauma start?

Studying the Modification of Attention Bias Remotely After Trauma started on 2023-04-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.